스타틴 시장 보고서 : 유형별, 치료 영역별, 약제 클래스별, 용도별, 유통별, 지역별(2024-2032년)

The global statin market size reached US$ 15.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 20.0 Billion by 2032, exhibiting a growth rate (CAGR) of 2.9% during 2024-2032. The market is experiencing steady growth driven by the increasing prevalence of cardiovascular diseases and hypercholesterolemia globally, the expanding healthcare infrastructure and the availability of insurance coverage for cholesterol-lowering medications bolster demand across the globe.

Statin Market Analysis:

Market Growth and Size: The global market is experiencing significant growth, driven largely by the increasing prevalence of cardiovascular diseases. With the rising demand for cholesterol-lowering drugs, the market size is expanding, reflecting a growing awareness and need for effective treatments in managing heart health.

Technological Advancements: Technological developments, particularly in the field of personalized medicine, are revolutionizing the statin market. Advances in genomics and bioinformatics are enabling more personalized treatment approaches, improving the efficacy of statins and reducing the risk of adverse effects, thus propelling market growth.

Industry Applications: Statins are primarily used in the healthcare industry for the prevention and treatment of cardiovascular diseases by lowering LDL cholesterol levels. Their application has become integral in managing heart health, especially in populations with high risk of heart diseases.

Key Market Trends: A notable trend in the statin market is the shift towards precision medicine, where treatments are tailored to individual genetic profiles. Additionally, there is an increasing focus on preventive healthcare measures, which is driving the demand for statins as a preventive medication for cardiovascular diseases.

Geographical Trends: The demand for statins is particularly high in regions with aging populations and those with prevalent lifestyle-related risk factors for heart diseases. Developed regions such as North America and Europe currently dominate the market, but there is a growing demand in emerging economies due to increasing health awareness and improving healthcare infrastructure.

Competitive Landscape: The global market is characterized by the presence of several key players, with competition driven by innovation, product development, and marketing strategies. The market is also witnessing collaborations between pharmaceutical companies and healthcare providers to enhance the accessibility and effectiveness of statin therapy.

Challenges and Opportunities: One major challenge in the market is addressing the adverse effects associated with statin use, which can affect patient compliance. However, this challenge presents an opportunity for the development of new statin formulations with fewer side effects. Additionally, the increasing incidence of cardiovascular diseases globally offers a substantial opportunity for market expansion.

Statin Market Trends:

Increasing prevalence of cardiovascular diseases

The rising incidence of cardiovascular diseases (CVDs) majorly drives the global market. Statins, known for their cholesterol-lowering properties, play a critical role in the management and prevention of CVDs. This growing health burden is leading to a growing awareness and proactive management of risk factors such as high LDL cholesterol. Therefore, this is positively influencing the market. Consequently, the demand for statins is escalating, driven by both the increasing number of patients and the growing emphasis on preventive healthcare. This trend is particularly noticeable in regions with aging populations and lifestyle-related risk factors, making statins a key component in the treatment and management of cardiovascular health.

Advancements in personalized medicine

The global market is also being propelled forward by significant advancements in personalized medicine. Personalized, or precision, medicine involves tailoring medical treatment to the individual characteristics of each patient, and in the case of statins, this involves considering genetic factors that affect an individual's response to these drugs. Additionally, research has shown that genetic variations can influence a person's response to statins, both in terms of efficacy and risk of side effects. As a result, there is an increasing focus on developing personalized treatment plans that optimize statin therapy. In addition, the integration of genomics and bioinformatics in healthcare is thus a key factor driving innovation and growth in the market.

Government initiatives and healthcare policies

Government initiatives and healthcare policies significantly influence the global market. Many governments across the world are implementing policies and programs to combat the rising incidence of heart disease. These initiatives often include guidelines for cholesterol management, which recommend the use of statins as a first-line therapy. Moreover, governments and healthcare organizations are increasingly focusing on preventive healthcare measures, recognizing the cost-effectiveness of preventing heart diseases rather than treating them post-occurrence. This shift in focus is leading to increased funding for public health campaigns that raise awareness about the importance of cholesterol management, thereby driving the demand for statins. Additionally, the inclusion of statins in national and international treatment guidelines further underscores their importance in cardiovascular health management and boosts their adoption in clinical practice.

Statin Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on type, therapeutic area, drug class, application, and distribution.

Breakup by Type:

Synthetic Statins

Natural Statins

Natural statins account for the majority of the market share

The report has provided a detailed breakup and analysis of the statin market based on the type. This includes synthetic statins and natural statins. According to the report, natural statins represented the largest segment.

Breakup by Therapeutic Area:

Cardiovascular Disorders

Obesity

Inflammatory Disorders

Others

A detailed breakup and analysis of the statin market based on the therapeutic area has also been provided in the report. This includes cardiovascular disorders, obesity, inflammatory disorders, and others.

Breakup by Drug Class:

Atorvastatin

Fluvastatin

Lovastatin

Pravastatin

Simvastatin

Others

Atorvastatin represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the drug class. This includes atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin, and others. According to the report, atorvastatin accounted for the largest market share.

Breakup by Application:

Dyslipidemia

Others

A detailed breakup and analysis of the statin market based on the application has also been provided in the report. This includes dyslipidemia and others.

Breakup by Distribution:

Hospitals

Clinics

Others

Hospitals dominate the market

The report has provided a detailed breakup and analysis of the market based on the distribution. This includes hospitals, clinics, and others. According to the report, hospitals accounted for the largest market share.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest statin market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AstraZeneca

Aurobindo Pharma

Biocon

GlaxoSmithKline

Merck & Co.

Novartis

Pfizer

Key Questions Answered in This Report

• 1. What was the size of the global statin market in 2023?
• 2. What is the expected growth rate of the global statin market during 2024-2032?
• 3. What are the key factors driving the global statin market?
• 4. What has been the impact of COVID-19 on the global statin market?
• 5. What is the breakup of the global statin market based on the type?
• 6. What is the breakup of the global statin market based on the drug class?
• 7. What is the breakup of the global statin market based on the distribution?
• 8. What are the key regions in the global statin market?
• 9. Who are the key players/companies in the global statin market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Statin Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Synthetic Statins
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Natural Statins
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Therapeutic Area

• 7.1 Cardiovascular Disorders
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Obesity
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Inflammatory Disorders
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Drug Class

• 8.1 Atorvastatin
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Fluvastatin
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Lovastatin
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Pravastatin
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Simvastatin
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast
• 8.6 Others
  • 8.6.1 Market Trends
  • 8.6.2 Market Forecast

9 Market Breakup by Application

• 9.1 Dyslipidemia
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Others
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast

10 Market Breakup by Distribution

• 10.1 Hospitals
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Clinics
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Others
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast

11 Market Breakup by Region

• 11.1 North America
  • 11.1.1 United States
    • 11.1.1.1 Market Trends
    • 11.1.1.2 Market Forecast
  • 11.1.2 Canada
    • 11.1.2.1 Market Trends
    • 11.1.2.2 Market Forecast
• 11.2 Europe
  • 11.2.1 Germany
    • 11.2.1.1 Market Trends
    • 11.2.1.2 Market Forecast
  • 11.2.2 France
    • 11.2.2.1 Market Trends
    • 11.2.2.2 Market Forecast
  • 11.2.3 United Kingdom
    • 11.2.3.1 Market Trends
    • 11.2.3.2 Market Forecast
  • 11.2.4 Italy
    • 11.2.4.1 Market Trends
    • 11.2.4.2 Market Forecast
  • 11.2.5 Spain
    • 11.2.5.1 Market Trends
    • 11.2.5.2 Market Forecast
  • 11.2.6 Russia
    • 11.2.6.1 Market Trends
    • 11.2.6.2 Market Forecast
  • 11.2.7 Others
    • 11.2.7.1 Market Trends
    • 11.2.7.2 Market Forecast
• 11.3 Asia Pacific
  • 11.3.1 China
    • 11.3.1.1 Market Trends
    • 11.3.1.2 Market Forecast
  • 11.3.2 Japan
    • 11.3.2.1 Market Trends
    • 11.3.2.2 Market Forecast
  • 11.3.3 India
    • 11.3.3.1 Market Trends
    • 11.3.3.2 Market Forecast
  • 11.3.4 South Korea
    • 11.3.4.1 Market Trends
    • 11.3.4.2 Market Forecast
  • 11.3.5 Australia
    • 11.3.5.1 Market Trends
    • 11.3.5.2 Market Forecast
  • 11.3.6 Indonesia
    • 11.3.6.1 Market Trends
    • 11.3.6.2 Market Forecast
  • 11.3.7 Others
    • 11.3.7.1 Market Trends
    • 11.3.7.2 Market Forecast
• 11.4 Latin America
  • 11.4.1 Brazil
    • 11.4.1.1 Market Trends
    • 11.4.1.2 Market Forecast
  • 11.4.2 Mexico
    • 11.4.2.1 Market Trends
    • 11.4.2.2 Market Forecast
  • 11.4.3 Others
    • 11.4.3.1 Market Trends
    • 11.4.3.2 Market Forecast
• 11.5 Middle East and Africa
  • 11.5.1 Market Trends
  • 11.5.2 Market Breakup by Country
  • 11.5.3 Market Forecast

12 SWOT Analysis

• 12.1 Overview
• 12.2 Strengths
• 12.3 Weaknesses
• 12.4 Opportunities
• 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

• 14.1 Overview
• 14.2 Bargaining Power of Buyers
• 14.3 Bargaining Power of Suppliers
• 14.4 Degree of Competition
• 14.5 Threat of New Entrants
• 14.6 Threat of Substitutes

15 Price Indicators

16 Competitive Landscape

• 16.1 Market Structure
• 16.2 Key Players
• 16.3 Profiles of Key Players
  • 16.3.1 Abbott
    • 16.3.1.1 Company Overview
    • 16.3.1.2 Product Portfolio
    • 16.3.1.3 Financials
    • 16.3.1.4 SWOT Analysis
  • 16.3.2 AstraZeneca
    • 16.3.2.1 Company Overview
    • 16.3.2.2 Product Portfolio
    • 16.3.2.3 Financials
    • 16.3.2.4 SWOT Analysis
  • 16.3.3 Aurobindo Pharma
    • 16.3.3.1 Company Overview
    • 16.3.3.2 Product Portfolio
    • 16.3.3.3 Financials
  • 16.3.4 Biocon
    • 16.3.4.1 Company Overview
    • 16.3.4.2 Product Portfolio
    • 16.3.4.3 Financials
    • 16.3.4.4 SWOT Analysis
  • 16.3.5 GlaxoSmithKline
    • 16.3.5.1 Company Overview
    • 16.3.5.2 Product Portfolio
    • 16.3.5.3 Financials
    • 16.3.5.4 SWOT Analysis
  • 16.3.6 Merck & Co.
    • 16.3.6.1 Company Overview
    • 16.3.6.2 Product Portfolio
    • 16.3.6.3 Financials
    • 16.3.6.4 SWOT Analysis
  • 16.3.7 Novartis
    • 16.3.7.1 Company Overview
    • 16.3.7.2 Product Portfolio
    • 16.3.7.3 Financials
    • 16.3.7.4 SWOT Analysis
  • 16.3.8 Pfizer
    • 16.3.8.1 Company Overview
    • 16.3.8.2 Product Portfolio
    • 16.3.8.3 Financials
    • 16.3.8.4 SWOT Analysis